No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Ascendis Pharma Files New Drug Application for Achondroplasia Medication
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading
UBS Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $196
Looking Into Ascendis Pharma's Recent Short Interest
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $200
